Abstract. Bromodomain and extra-terminal domain (BET) family proteins are representative epigenetic modulators that read acetylated lysine residues and transfer cellular signals. Recently, the BET protein inhibitor JQ1 was developed and has been extensively studied in many cancer cell types. We demonstrated that JQ1 effectively suppressed the MYC-AP4 axis and induced antitumorigenic effects by targeting a bidirectional positive loop between MYC and AP4 which was first proposed in the present study. MYC and AP4 are the direct targets of BRD4, as demonstrated by chromatin immunoprecipitation (ChIP) assay and BRD4 loss-of-function experiments. Although inhibition of the MYC/MAC dimer suppressed AP4, the efficacy of suppression was not as effective as BRD4 inhibition. Notably, AP4 loss-of-function studies demonstrated that AP4 is a major critical target of JQ1 and that MYC is a novel downstream target of AP4, as demonstrated by AP4 binding to the MYC promoter. Taken together, our results suggest that the epigenetic reader BRD4 is a key mediator of the activated MYC-AP4 axis, which supports the possibility that targeting BET protein is a novel therapeutic strategy for MYC-AP4 axis-activated cancers.
Introduction
Epigenetic mechanisms regulate gene expression and establish cellular identity. Therefore, the absence of proper epigenetic marks contributes to the development of diseases including cancer (1) . These epigenetic marks are recognized by reader proteins that interpret the chromatin information and signal other cellular components to facilitate chromatin remodeling (2, 3) . Proteins in the bromodomain and extra-terminal domain (BET) family, including bromodomain-containing proteins (BRD)2, BRD3, BRD4, and BRDT (testis-specific), are well-known readers of acetyl lysine residues, which is not only the most abundant protein modification in cells but also is critical to chromatin structure. BETs regulate a variety of genes involved in the cell cycle, cell growth and inflammation (4) . Thus, the targeting of these BETs has become an intense research issue in diverse therapeutic areas.
The proto-oncogene MYC is a transcription factor containing a basic helix-loop-helix (bHLH) domain that has been studied for more than 30 years. The biology of MYC has been studied extensively which has resolved various issues. MYC heterodimerizes with the bHLH protein MAX and binds to CA(C/T)GTG of its target genes. These genes encompass a broad spectrum of functions, from cell cycle progression and cell growth to epithelial-mesenchymal transition (EMT) (5) . Activating enhancer binding protein 4 (AP4) is considered a key mediator of mitogenicity for MYC and EMT, as well as for further metastasis (6, 7) . MYC directly binds to CACGTG motifs in the first intron of the AP4 and functions as an activator (7) . AP4 protein belongs to the bHLH subfamily similar to MYC, although it recognizes symmetrical DNA sequences such as CAGCTG and exclusively forms homodimers (7, 8) . The role of the MYC-AP4 axis in cell cycle regulation and tumorigenesis was only recently discovered (8) . Although a number of studies have reported MYC amplification and/or overexpression in several types of cancers (9) , targeting of the MYC or MYC-AP4 axis remains a distant challenge.
Recently, a potent, selective, small-molecule inhibitor of BET bromodomains, JQ1, was developed. The molecule antagonized BET bromodomain proteins during MYC-dependent transcription in several types of cancers, including multiple JQ1, an inhibitor of the epigenetic reader BRD4, suppresses the bidirectional MYC-AP4 axis via multiple mechanisms myeloma, acute myeloid leukemia and mixed lineage leukemia (10) (11) (12) . However, a more recent study suggested that the efficacy of BET inhibitors is not always dependent on the downregulation of MYC (13) . With characteristic targeting epigenetic signaling molecules, BET inhibitors may function differently in a cell context-dependent manner. Therefore, it is important to define the main target and underlying mechanism of BET inhibitors in different cellular contexts. Breast cancer is the most frequent type of cancer diagnosed in women and is a representative heterogeneous disease that can be classified into several subtypes based on gene expression profiling and tumor histology (14) . Approximately 75% of patients are hormone receptor-positive, and the treatment options for these patients have relied on anti-hormonal strategies. While most patients respond to endocrine agents and have shown improved overall survival, eventually, the majority of such patients become resistant to these agents (15) . Development of a therapeutic strategy to combat this resistance and to effectively treat hormone receptor-negative breast cancer is crucial. Recent studies have shown that BET inhibitors are valuable candidates for overcoming resistance to endocrine agents by the suppression of MYC and PI3K signaling (16, 17) .
In the present study, we determined whether JQ1, an inhibitor of the epigenetic reader BRD4, suppresses the MYC-AP4 axis in breast cancer. We found that JQ1 suppressed the MYC-AP4 axis in ER-positive and -negative breast cancer cell lines. We further studied the ER-negative breast cancer cell line MDA-MB-231 which is relative harder to target in the clinic. JQ1 downregulated the MYC-AP4 axis by direct inhibition of BRD4 binding to the MYC and AP4 promoters at early time-points and subsequently induced antitumorigenic effects, including cell cycle arrest, reduced wound healing, and soft agar colony formation. using BRD4 loss-of-function experiments, we further demonstrated that MYC and AP4 are the direct targets of BRD4 inhibition. We found that loss of AP4 mimics almost all of the antitumorigenic effects of JQ1, suggesting that AP4 is a more sensitive target for BRD4-mediated inhibition of MDA-MB-231 cells. Of note, we demonstrated for the first time that MYC is a downstream target of AP4; hence, there is a bidirectional positive loop between MYC and AP4. Thus, inhibition of the MYC-AP4 axis can be better amplified by JQ1. Altogether, the results presented here demonstrate that the BET protein inhibitor is effective against MYC-AP4 axis-activated cancers and other diseases by targeting multiple points.
Materials and methods
RNA extraction and reverse transcription PCR. Total RNA was extracted using TRIzol reagent, digested with DNase I, and reverse transcribed using a High Capacity cDNA reverse transcription kit (Applied Biosystems). Amplification of cDNA was performed on a LightCycler ® 480 Ⅱ using the LightCycler ® 480 SYBR Green Ⅰ Master (both from Roche), using the recommended conditions. cDNAs were amplified using the following gene-specific primers: RT_MYC, 5'-CCCTGG TGCCGTGAAGC; 3'-TTGCTCGAGTTCTTTCTGCAGA; and RT_AP4, 5'-GCAGGCAATCCAGCACAT; 3'-GGAGGC GGTGTCAGAGGT; and RT_P21, 5'-GAGGCCGGGATG (w/v) dry skim milk powder, and incubated overnight with the primary antibodies (dilution ratio 1:1,000). The membranes were then washed with TBS-0.1% Tween-20, incubated for 1 h with a secondary antibody (dilution ratio 1:10,000), and visualized using an enhanced chemiluminescence detection kit (Amersham Life Sciences) after exposure on an LAS-3000 image detection system (Fuji). Cell cycle analysis. Cell cycle assays were performed using the Cycletest Plus DNA reagent kit (BD Biosciences), according to the manufacturer's instructions. The cell cycle profile of the cells was analyzed using a FACScan flow cytometer (BD Biosciences).
Chromatin immunoprecipitation assay (ChIP
Soft agar colony-formation assay. The soft agar colonyformation assay was performed in 6-well plates. A bottom layer of agar (0.5%) with enriched Dulbecco's modified Eagle's medium (DMEM) (final 10% FBS) was initially poured. After the bottom agar solidified, MDA-MB-231 cells (1.0x10 4 ) were seeded on the top agar (0.3%) with enriched DMEM (final 10% FBS) and incubated at 37˚C for 21 days. The culture medium was replaced 1-2 times per week. Colonies were visualized by staining for 1 h with 0.005% crystal violet.
Wound-healing assay. Cells were grown to confluency in culture dishes and treated with 0.2 µM JQ1. After overnight starvation in serum-free medium, the cell monolayers were scraped with a sterile micropipette tip. Initial gap widths (0 h) and residual gap widths at 6 and 24 h after wounding were determined by photomicrographs.
shRNA infection. shBRD4 and shAP4 constructs were purchased from Sigma-Aldrich. For lentiviral production, the Mission lentiviral packaging mix was used. Infected derivative cells stably expressing shRNA were selected in the presence of 1.25 µg/ml puromycin.
Statistical analysis.
Results are expressed as mean ± SEM. Most statistical comparisons were calculated by one-way ANOVA followed by Bonferroni's post hoc test using GraphPad Prism. A p-value <0.05 was considered to indicate a significant result.
Results

JQ1 suppresses the MYC-AP4 axis in breast cancer cell lines.
To examine whether JQ1, a known BRD4 inhibitor, targets the MYC-AP4 axis in breast cancer cells, we used ER-negative MDA-MB-231 cells and ER-positive MCF7 cells as models. MDA-MB-231 and MCF7 cells were treated for 24 h with the indicated concentrations of JQ1 (Fig. 1) . The morphology of the MDA-MB-231 cells became thinner with protrusions after treatment with increasing concentrations of JQ1 (Fig. 1A) . In contrast, JQ1 had a modest effect on the morphology of the MCF7 cells (Fig. 1D) . JQ1 suppressed the MYC-AP4 axis in a dose-dependent manner in the MDA-MB-231 and MCF7 cells, although the sensitivities differed (Fig. 1B, C, E and F) . MCF7 cells were more sensitive than the MDA-MB-231 cells to suppression by JQ1; this sensitivity may have been caused by a slightly higher expression of MYC in the MDA-MB-231 cells (Fig. 1) . upregulation of P21 expression was accompanied by downregulation of MYC and AP4 (Fig. 1B, C, E and F) , indicating that JQ1 targets the MYC-AP4 axis in both ER-negative and -positive breast cancer cell lines.
JQ1 suppresses the tumorigenicity of breast cancer cells.
Based on a previous study showing that acute treatment with JQ1 inhibits BRD4 (11), we measured the suppression of the MYC-AP4 axis by JQ1 (0.2 µM) at an early time-point in the MDA-MB-231 and MCF7 cells. Downregulation of MYC and AP4 was observed after 6 h of treatment, and was accompanied by upregulation of P21 ( Fig. 2A-D) . Notably, the protein level of AP4 was almost completely abolished at 6 h post-treatment in both breast cancer cell lines (Fig. 2B and D) , suggesting that AP4 is a highly sensitive and direct target of JQ1.
The MYC-AP4-P21 axis is responsible for G1 arrest in several types of cancer cells (8) ; therefore, we investigated the effect of JQ1 on the cell cycle. JQ1 treatment led to an increase in the percentage of cells in the G1 stage, from 64 to 85% in the MDA-MB-231 cells and from 55 to 86% in the MCF7 cells (Fig. 2E) . Next, to assess additional antitumorigenic effects of JQ1, we performed a scratch wound-healing assay and a soft agar colony-formation assay using MDA-MB-231 cells. As shown in Fig. 2F and G, JQ1 efficiently reduced the wound-healing capacity and soft agar colony formation of the MDA-MB-231 cells, indicating that JQ1 has antitumor efficacy in breast cancer cells.
JQ1 negatively regulates the MYC-AP4 axis directly via suppression of BRD4 binding at the promoters of both genes.
To determine whether downregulation of MYC and AP4 by JQ1 is associated with BRD4 binding, we performed chromatin immunoprecipitation (ChIP) with a BRD4 antibody in MDA-MB-231 cells (Fig. 3A and B) . First, we measured BRD4 binding to the previously identified promoter, enhancer 1 and enhancer 2 of MYC (11) . As shown in Fig. 3A , we found that BRD4 binding decreased early at the promoter and at enhancer 2 upon treatment with JQ1, but not at enhancer 1. Next, we measured BRD4 binding to the previously identified promoter, enhancer 1 and enhancer 2 of AP4 (7). Reduced binding by BRD4 was detected, mainly in the promoter, rather than in the enhancers (Fig. 3B) , suggesting that suppression of the MYC-AP4 axis is through the direct inhibition of BRD4 binding at the promoter of both genes.
To further establish that BRD4 is required for activation of the MYC-AP4 axis, we performed a loss-of-function study by generating stable BRD4-knockdown cells (Fig. 3C) . We detected reduced expression of MYC and AP4 as well as an increase in P21 after BRD4 knockdown in the MDA-MB-231 cells (Fig. 3D) , demonstrating that, in MDA-MB-231 cells, the MYC-AP4 axis is a direct target of the epigenetic reader, BRD4.
Inhibition of MYC/MAX heterodimerization suppresses AP4, but not as effectively as JQ1.
To determine whether the activation of the MYC-AP4 axis occurs through the action of the MYC/MAX dimer, we used the small-molecule MYC inhibitor, 10058-F4. 10058-F4 prevents the binding of MYC/MAX dimers to targets and inhibits MYC-driven transformation (18, 19) . While 10058-F4 did not alter MYC mRNA levels, a dose of 50 µM downregulated AP4 mRNA. This dose was also sufficient to induce changes in cell morphology (Fig. 4A and C) , suggesting that AP4 is a target of the MYC/MAX dimer. There was a partial decrease in the MYC and AP4 protein levels after treatment with 10058-F4 (Fig. 4B) , and the effect of 10058-F4 on cell cycle arrest was mild when compared to the effect of JQ1 (Fig. 4D) . These results suggest that inhibition of MYC/MAX dimerization in the activated MYC-AP4 axis is not as effective as BRD4 inhibition, presumably due to a smaller downregulation of AP4.
Knockdown of AP4 reveals a bidirectional, positive loop between MYC and AP4 and the underlying mechanism by which suppression of the MYC-AP4 axis is synergized after treatment with JQ1.
To determine whether AP4 is the major target of BRD4 inhibition, we generated a stable AP4-knockdown cell line using shRNA in the MDA-MB-231 cells. We then analyzed the mRNA and protein expression of AP4, MYC, and P21 ( Fig. 5A and B) . We verified complete loss of AP4 by western blot analysis (Fig. 5B) and found that loss of AP4 mimicked most of the effects of treatment with JQ1, including suppression of the MYC-AP4 axis and subsequential induction of P21 (Fig. 5A and B) , changes in cell morphology (Fig. 5C ), cell cycle arrest (Fig. 5D) , and reduced soft agar colony formation (Fig. 5E) . These results suggest unexpectedly, we observed a decrease in MYC upon AP4 knockdown ( Fig. 5A and B) . AP4 is known to be a direct target of MYC (6,7) ; however, to the best of our knowledge, it has not been reported that MYC is a downstream target of AP4. To confirm that MYC is a downstream target of AP4 and that there is a bidirectional positive loop between MYC and AP4, we performed a ChIP assay using the AP4 antibody following JQ1 treatment. We identified an AP4 binding motif (CAGCTG) within the MYC promoter. We detected AP4 binding at this site, and this binding decreased upon treatment with JQ1 (Fig. 5F ), demonstrating that MYC is a downstream target of AP4. Taken together, these data suggest that suppression of the MYC-AP4 axis by JQ1 is synergized through multiple mechanisms, including inhibition of BRD4 binding at the MYC and AP4 promoters, followed by secondary inhibition of a bidirectional loop between MYC and AP4. (Fig. 5G) . JQ1 inhibited BRD4 binding mainly at the promoters for MYC and AP4 promoters, rather than at the enhancer sites. We further demonstrated that MYC and AP4 are direct targets of BRD4 by generating stable BRD4-knockdown breast cancer cell lines. We found that the suppressive effect of an inhibitor of MYC/MAX dimerization on the activated MYC-AP4 axis was not as effective as inhibition of BRD4, which presumably acts through the mild downregulation of AP4. Our AP4 loss-of-function study demonstrated that AP4 is a major critical target of JQ1 and that MYC is a novel target of AP4, which was further supported by an anti-AP4 ChIP assay. Downregulation of MYC-AP4 by inhibition of BRD4 induced antitumorigenic effects, including cell cycle arrest, reduced wound healing and soft agar colony formation. Collectively, our results suggest that the epigenetic reader BRD4 is a key mediator of the overexpression of MYC and AP4. These findings have important implications for the treatment of MYC-AP4 axis-activated cancers.
Inhibitors of the epigenetic reader BET family, including JQ1 and I-BET, have emerged as promising therapeutic drugs for cancers, inflammation and obesity (20) . The underlying mechanisms of the effects of these small molecules often involve binding of these drugs to the bromodomain of BET proteins, and the process is completed upon lysine acetylation of histones. The molecules, therefore, suppress target gene expression involved in tumorigenesis or the inflammatory response (4, 20) . MYC is the primary target in several cancers (11, 12, 21) , and more recently, the underlying mechanism was proposed to involve inhibition by JQ1 of MYC by disrupting super-enhancers (22) . Super-enhancers are defined as large clusters of enhancers that determine cellular identity (23, 24) . JQ1 was found to lead to preferential loss of BRD4 at super-enhancers of MYC in multiple myeloma (22) ; however, it is not clear whether MYC always has a super-enhancer in different cellular contexts. Indeed, our results demonstrated that JQ1 inhibited BRD4 binding to the MYC promoter and enhancer 2, but not to enhancer 1 (Fig. 3A) . Thus, the detailed molecular mechanism of BET protein inhibitors requires further investigation.
AP4 is known to be a MYC-inducible repressor of P21 (7); however, it has not been previously reported that MYC is a downstream target of AP4. Here, we demonstrated, for the first time, that there is a bidirectional positive loop between MYC and AP4 (Fig. 5) . As shown in Fig. 5 , AP4 binds to the MYC promoter. Binding by AP4 is reduced by JQ1 treatment, and knockdown of AP4 induces downregulation of MYC. This may be the underlying mechanism by which suppression of the MYC-AP4 axis is amplified by the BET protein inhibitor. AP4 is also known to contribute to several processes during cancer development, including EMT and metastasis (6) . Our study showed that JQ1 downregulated AP4 at a very early time point and at low concentrations in the ER-positive and -negative cancer cell lines (Figs. 1 and 2) . These results suggest that AP4 is the most sensitive and critical target of BET protein inhibition. The clinical relevance of AP4 expression in cancers was previously reported. Elevated expression of AP4 is associated with an increased metastatic capacity in colorectal cancer (6) and AP4 predicts poor prognosis in non-small cell lung cancer (25) . In addition, several studies have demonstrated the critical role of AP4 in cancers and in immunology (26) (27) (28) . Therefore, this study contributes to our understanding of cancer biology.
It is well known that epigenetic modifiers and chromatin remodelers control gene expression and establish cellular identities via the regulation of chromatin structure. However, little is known concerning the specific targets of these components of the epigenome and the underlying mechanisms of the effects of the small molecules that target them. Our results showed, for the first time, that the BET protein inhibitor suppressed the MYC-AP4 axis by targeting a bidirectional loop between MYC and AP4 to induce antitumorigenic effects. Collectively, our results suggest that a better understanding of epigenetic modifiers and chromatin remodelers will facilitate the development of novel strategies for treating many diseases caused by dysregulated epigenome components.
